Close

Jefferies Likes Early Iclusig Sales Data for ARIAD Pharmaceuticals (ARIA)

Go back to Jefferies Likes Early Iclusig Sales Data for ARIAD Pharmaceuticals (ARIA)

Goldman Sachs Starts ARIAD Pharmaceuticals (ARIA) at Neutral

March 28, 2013 7:26 AM EDT

Goldman Sachs initiates coverage on ARIAD Pharmaceuticals (NASDAQ: ARIA) with a Neutral. PT $20.00.

With shares up 55% since reporting the initial pivotal data for Iclusig on December 11, 2011, and valuation at a premium to peers, they see current valuation as fair.

For an... More